COMMUNIQUÉS West-GlobeNewswire

Avis aux médias: L’Hôpital Shriners pour enfants Canada ouvre ses portes au public le 29 novembre pour souligner son 100e anniversaire
26/11/2025
MONTRÉAL, 26 nov. 2025 (GLOBE NEWSWIRE) -- Quoi : Dans le cadre des célébrations de son centenaire, l’Hôpital Shriners pour enfants Canada invite les familles à prendre part à une journée portes ouvertes qui allie [...]
Media advisory: Shriners Hospitals for Children Canada Opens Its Doors to the Public on November 29 in Honour of Its 100th Anniversary
26/11/2025
MONTREAL, Nov. 26, 2025 (GLOBE NEWSWIRE) -- What: Families looking for an educational and fun weekend activity are invited to discover Shriners Hospitals for Children Canada during its Open House. Children can enjoy [...]
Moleculin to Participate in the Virtual Investor Closing Bell Series
26/11/2025
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2 nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the [...]
Wake Radiology Moves its Chapel Hill Office to the Timberlyne Neighborhood
26/11/2025
New footprint offers a modern, conveniently accessible facility primed for continued office growth RALEIGH, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Wake Radiology UNC Health Rex, the largest outpatient imaging provider [...]
First Rate Infusion & Wellness Launches Mobile “Vitamins in a Bag” Program to Support Employee Wellness Across Dallas–Fort Worth
26/11/2025
First Rate Infusion & Wellness Expands Services With Mobile IV Hydration Offering for Employers in the Dallas–Fort Worth Region Mesquite, Texas, Nov. 26, 2025 (GLOBE NEWSWIRE) -- First Rate Infusion & Wellness, [...]
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
26/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will [...]
Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.
26/11/2025
Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot exchange rate of [...]
Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025
26/11/2025
TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved [...]
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
26/11/2025
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to [...]
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
26/11/2025
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah [...]
CG Oncology Announces New Board Member and Board Transition
26/11/2025
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical [...]
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
26/11/2025
Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the [...]
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
26/11/2025
Kuros Biosciences to present at the Piper Sandler 37 th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic [...]
Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vaccin contre la maladie de Lyme
26/11/2025
Les taux d'anticorps sont restés supérieurs à leur niveau initial pour les six sérotypes et dans toutes les tranches d’âge six mois après la dernière injection des trois doses de rappel Aucun problème de sécurité n’a [...]
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
26/11/2025
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee ( [...]
Galapagos Receives Transparency Notifications from Bank of America
26/11/2025
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation [...]
La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS
26/11/2025
La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS L'attribution à l’APC "nouvelle technologie" 1580 donne un élan significatif [...]
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
26/11/2025
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening [...]
Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate
26/11/2025
The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into [...]

Pages